Here are relevant reports on : attention-deficit-hyperactivity-disorder-therapeutics-market
-
Aptamers Market by Product Type (DNA, RNA, XNA), Technology (SELEX), Application (Therapeutics, Diagnostics, R&D), End Users (Pharmaceutical & Biotechnology Companies, Academic & Government Research Institutes, CROs) - Global Forecast to 2026
The global aptamers market growth is primed to transition from $151 million in 2021 to $342 million by 2026, showcasing a strong CAGR of 17.7%. Growth of the market is attributed to factors such as increase in number of clinical trials for development of aptamer-based therapeutics, increase in awareness about advantages of aptamers as compared to antibodies, rising investment in pharmaceutical R&D, and rising prevalence of chronic and rare diseases to increase the demand for aptamer-based therapeutics and diagnostics. Growth in the venture capital funding for research on aptamers and growing collaborations with research institutes and pharmaceutical companies are also expected to offer a wide range of growth opportunities to players in the market.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Microfluidics Market by Product (Chip, Sensor, Valve, Pump, Needle), Material (Silicon, Polymer), Application [Diagnostics (Clinical, PoC), Research (Proteomics, Genomics, Cell), Therapeutics (Drug Delivery Wearables)], End User – Global forecast to 2030
The global Microfluidics market, valued at US$23.71 billion in 2024, stood at US$24.96 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2030, culminating in a forecasted valuation of US$37.19 billion by the end of the period. Several significant factors are driving the growth of the microfluidics market, thereby enhancing its expansion and applications. There is a growing demand for point-of-care diagnostics, which require fast, accurate, and cost-effective instruments.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Oligonucleotide Therapeutics Market by Molecule (Nusinersen, Vutrisiran, Inclisiran, Eteplisiran), Type (ASO, siRNA, Others), Disease Type (Neurology, Rare Diseases, Others), RoA (SC, Intrathecal, IV, Others), and Region - Global Forecast to 2030
The global oligonucleotide therapeutics market, valued at US$5.92 billion in 2024, stood at US$7.19 billion in 2025 and is projected to advance at a resilient CAGR of 19.7% from 2025 to 2030, culminating in a forecasted valuation of US$17.70 billion by the end of the period. The market is growing as more RNA-targeting therapies gain broader clinical acceptance. This increase is mainly driven by siRNAs and antisense candidates, supported by advances in delivery technologies like GalNAc conjugates and lipid nanoparticles.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
mRNA Therapeutics Market by Product (Vaccines, Drugs), Application (Oncology, Rare Diseases, Infectious Diseases, Other Applications), End User (Hospitals & Clinics, Research Settings) - Global Forecast to 2027
The global mRNA therapeutics market is projected to reach USD ~35 billion by 2027 from USD 32 billion in 2022, at a CAGR of ~2% between 2022 and 2027.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Digital Therapeutics Market / DTx Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) - Global Forecast to 2028
The global digital therapeutics market, valued at US$4.4 billion in 2022, stood at US$6.1 billion in 2023 and is projected to advance at a resilient CAGR of 29.1% from 2023 to 2028, culminating in a forecasted valuation of US$21.9 billion by the end of the period. The rapid adoption of digital therapeutics is driven by the rising incidence of chronic diseases, surging investments from venture capital firms, and strategic partnerships between tech companies and healthcare providers.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
US Medical Gas and Equipment Market by Type [Medical Gas (Oxygen, Nitrous Oxide), Medical Gas Equipment (Flowmeter, Others)], Application [Therapeutics, Diagnostics], End User [Hospital, Home Healthcare] Forecast to 2031
The US Medical Gas and Equipment Market, valued at USD 8.18 million in 2024, stood at USD 8.63 million in 2025 and is projected to advance at a resilient CAGR of 6.5% from 2025 to 2031, culminating in a forecasted valuation of USD 11.97 million by the end of the period. The growth of the medical gas and equipment market in US is primarily driven by the rising incidence of respiratory and chronic diseases, including COPD, asthma, cardiovascular disorders, and sleep apnea, as well as a rapidly aging population that requires long-term oxygen therapy and critical care support.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Legal Marijuana Market by Strain Type ( Cannabis Indica, Cannabis Sativa ), Product ( Dried Cannabis, Oils, Capsules and Others ), Indication ( Chronic Pain, Arthritis, Neurological Disorder, Cancer and Other Indications ), Distribution Channel ( Hospital Pharmacy, Dispensaries and E-commerce ) and Region ( North America, Europe, Asia-Pacific, and LATAM & MEA )- Global Forecast to 2023
Cannabis, also known as marijuana, is a plant that is known for its psychoactive, medicinal, and fibrous properties. Medical cannabis has been proven effective in treating various medical conditions such as chronic pain, arthritis, seizure disorders, Crohn’s disease, and Parkinson’s disease; it is also found to be effective in reducing nausea caused due to chemotherapy, stimulating appetite in AIDs patients, controlling muscular spasms caused by multiple sclerosis, and reducing intraocular pressure in patients suffering from glaucoma.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Oxygen Concentrators Market by Type (Portable, Stationary), Technology (Continuous and Pulse Flow), Flowrate (0-5L/Min, 5-10L/Min, Above 10L/Min), Application (Chronic Obstructive Pulmonary Disorder), End User (Home Care Settings) - Global Forecast to 2030
The global oxygen concentrators market, valued at US$1.20 billion in 2024, stood at US$1.27 billion in 2025 and is projected to advance at a resilient CAGR of 6.1% from 2025 to 2030, culminating in a forecasted valuation of US$1.71 billion by the end of the period. Air pollution and smoking drive up demand for oxygen concentrators due to their role in worsening respiratory diseases like COPD and asthma, especially in urban and industrial areas.
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Adipose Derived Stem Cell Market by Type (Autologous, Allogeneic), Product (Cell Line. Culture Media), Disease (CVS, CNS, MSK, Obesity, Cancer), End User (Hospitals, Tissue Banks, Academia), Application (Therapeutics, Research) - Global Forecasts to 2019
Emerging markets including China, India, South Korea, and Brazil have become attractive destinations for companies engaged in the development and manufacturing of adipose derived stem cell products. A number of factors such as growing preference for use of adipose derived stem cells in therapeutics and emerging markets offering low regulatory barriers for conducting clinical studies are offering new growth opportunities for players active in the global adipose derived stem cell market
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Leukemia Therapeutics Market by Type (CLL, ALL, CML, AML), Treatment Type (Chemotherapy & Targeted Drugs by (CLL, ALL, CML, AML)), Mode of Administration (Oral, Injectable), Molecule Type (Small Molecules, Biologics), Gender, and Region - Global Forecast to 2024
The leukemia therapeutics market is projected to reach USD 17.1 billion by 2024, at a CAGR of 6.8%. Market growth is largely driven by the rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML) and increasing approvals of novel & innovative drugs and immunotherapies. The major players in this market are AbbVie (US), Bristol-Myers Squibb (US), Novartis (Switzerland, F. Hoffmann-La Roche (Switzerland), Pfizer (US), Sanofi (France), Amgen (US), Gilead Sciences (US), Takeda Pharmaceutical (Japan), and Celgene (US). Product approvals are a key strategy adopted by key players in order to enhance their dominance in this market.
- Published: May 2019
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
